Patents by Inventor John Puisis

John Puisis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COVALENT POLYMER-ANTIGEN CONJUGATED PARTICLES
    Publication number: 20260144891
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: October 24, 2025
    Publication date: May 28, 2026
    Inventors: Ryan Pearson, Daniel R. Getts, John Puisis, James Herrmann, Lonnie D. Shea
  • Covalent polymer-antigen conjugated particles
    Patent number: 12502436
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: October 24, 2022
    Date of Patent: December 23, 2025
    Assignees: COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC., REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ryan Pearson, Daniel Getts, John Puisis, James Herrmann, Lonnie D. Shea
  • Tolerizing Immune Modifying Nanoparticles for Overcoming the Immunogenicity of Therapeutic Vectors and Proteins
    Publication number: 20250367274
    Abstract: The present application is directed, in general, to tolerizing immune mediated particles comprising gene therapy vector antigens for use in combination with gene therapy regimens in order to reduce immunogenicity to the gene therapy vector antigens and/or transgene protein products expressed by the vectors.
    Type: Application
    Filed: April 28, 2023
    Publication date: December 4, 2025
    Inventors: John Puisis, Adam Elhofy, Joseph Podojil, Michael Boyne, Tushar Murthy
  • PREPARATION OF TOLERIZING NANOPARTICLES FOR THE TREATMENT OF PEANUT ALLERGY
    Publication number: 20250319155
    Abstract: The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating peanut proteins, compositions comprising the particles and use thereof for the treatment of peanut allergy.
    Type: Application
    Filed: November 23, 2022
    Publication date: October 16, 2025
    Inventors: John Puisis, Michael Boyne, Samantha Reilly, Greta Wodarcyk, Qichen Xu, Zhiyi Lin, Timothy Toby
  • TREATMENT OF SOLID TUMORS WITH NEGATIVELY CHARGED PARTICLES
    Publication number: 20250170066
    Abstract: The present disclosure generally relates to the methods of treating solid tumors using negatively charged particles.
    Type: Application
    Filed: February 27, 2023
    Publication date: May 29, 2025
    Inventors: John Puisis, Adam Elhofy, Michael Boyne, Joseph Podojil, Tushar Murthy
  • TREATMENT OF PEANUT ALLERGY WITH TOLERIZING NANOPARTICLES
    Publication number: 20240197866
    Abstract: The present disclosure relates, in general to methods of treating peanut allergy using nanoparticles encapsulating peanut antigens to induce antigen-specific tolerance.
    Type: Application
    Filed: April 15, 2022
    Publication date: June 20, 2024
    Inventors: John Puisis, James Herrmann, Michael Boyne, Adam Elhofy, Joseph Podojil, Greta Wodarcyk
  • Method of Tracking Maintenance of Immunological Tolerance
    Publication number: 20240201187
    Abstract: The present application relates, in general, to methods for tracking the induction of and long-term maintenance of antigen specific immune tolerance during administration of an antigen specific immune tolerizing therapy, such as a TIMP.
    Type: Application
    Filed: April 15, 2022
    Publication date: June 20, 2024
    Inventors: John Puisis, James Herrmann, Michael Boyne, Adam Elhofy, Joseph Podojil, Greta Wodarcyk
  • COVALENT POLYMER-ANTIGEN CONJUGATED PARTICLES
    Publication number: 20230338576
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: October 24, 2022
    Publication date: October 26, 2023
    Inventors: Ryan Pearson, Daniel Getts, John Puisis, James Herrmann, Lonnie D. Shea
  • NEGATIVELY CHARGED PARTICLES FOR THE TREATMENT OF CYTOKINE STORM SYNDROME (CSS) AND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
    Publication number: 20230190895
    Abstract: Provided herein are compositions that comprise negatively charged particles and methods of making and using the same. Also provided are methods of reducing or treating Cytokine Storm Syndrome (CSS) or Acute Rcspiratoiy Distress Syndrome (ARDS).
    Type: Application
    Filed: April 29, 2021
    Publication date: June 22, 2023
    Applicant: onCOUR Pharma, Inc.
    Inventors: John PUISIS, Jim HERRMANN
  • Covalent polymer-antigen conjugated particles
    Patent number: 11510996
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 29, 2022
    Assignees: COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ryan Pearson, Daniel Getts, John Puisis, James Herrmann, Lonnie D. Shea
  • TREATMENT OF IMMUNE EVASIVE TUMORS
    Publication number: 20220257768
    Abstract: The present disclosure provides methods of treating immune evasive cancers using surface functionalized particles alone or in combination with cancer therapeutics.
    Type: Application
    Filed: July 31, 2020
    Publication date: August 18, 2022
    Inventors: John PUISIS, Adam ELHOFY, Tushar MURTHY, Michael BOYNE, Joseph PODOJIL
  • IMMUNE MODIFYING PARTICLES FOR THE TREATMENT OF CANCER
    Publication number: 20210290661
    Abstract: The present disclosure provides methods of treating cancer and proliferative diseases using immune-modifying particles in combination with cancer therapeutics, such as checkpoint inhibitors or biologic agents, to modify the activity of myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), neutrophils, monocytes, and/or tumor-associated stroma associated with promoting tumor growth and metastasis.
    Type: Application
    Filed: July 31, 2019
    Publication date: September 23, 2021
    Inventor: John PUISIS
  • Immune-modifying nanoparticles for the treatment of inflammatory diseases
    Patent number: 11045492
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 29, 2021
    Assignee: onCour Pharma, Inc.
    Inventor: John Puisis
  • COVALENT POLYMER-ANTIGEN CONJUGATED PARTICLES
    Publication number: 20190282707
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: December 22, 2016
    Publication date: September 19, 2019
    Inventors: Ryan Pearson, Daniel R. Getts, John Puisis, James Herrmann